RESEARCH TRIANGLE PARK, N.C. & PARIS, FRANCE – August 2, 2011 – Quintiles, the world’s leading biopharmaceutical services company, and Kadrige, the market leader in e-detailing and multichannel sales solutions for the pharmaceutical and healthcare industries, today announced the opening of the first Kadrige office in the U.S.
By establishing a presence at Quintiles’ regional headquarters in Parsippany, N.J., Paris-based Kadrige is accelerating its international development plan for the North American region. In the U.S., Kadrige is building a team of consultants, sales professionals, project managers and information technology engineers to market the full range of services that enable biopharma to benefit from next generation medical call solutions.
In late 2010, Quintiles and Kadrige signed a co-promotion agreement covering Europe and the U.S. to offer solutions that help biopharma customers reduce one of their largest fixed costs by transitioning to a “hybrid” sales model. This blends face-to-face physician discussions with live, remote e-detailing calls via the telephone and internet. Quintiles and Kadrige are also developing Web-Call centers, which allow sales representatives to train or call on healthcare professionals via the Internet.
“The U.S. office opening is a natural evolution for the Kadrige/Quintiles alliance,” said Hubert Catanese, Managing Director at Kadrige. “North America is the leading global pharmaceutical market and the New Jersey, New York and Philadelphia triad hosts the headquarters of many major biopharma companies, some of which are already our customers. We have won several major contracts with leading North American groups who have chosen to rely on Kadrige medical hybrid calls to expand their market share.”
The creation of a local team in the U.S. will allow Kadrige to closely oversee ongoing projects, develop its business activity locally and provide quality support to its U.S. partners.
“In the changing world of biopharma, we call the New Health, we are providing the solutions our customers need through innovative technology and more than 10,000 field sales representatives,” said Michael Ackermann, Senior Vice President of Commercialization for Quintiles. “The goal is to set the standard for physician detailing, with a complete solution offering that integrates technology and face-to-face contact. Together, Quintiles and Kadrige can empower physicians with the most up-to-date, reliable information about the therapies that can help improve the lives of patients.”
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.
Kadrige is the European leader in SaaS (Software-as-a-Service) e-detailing and e-conferencing solutions. Its deep understanding of the complex requirements of the pharmaceutical industry professionals has enabled the development of high performance and innovative solutions and services. Kadrige offers software solutions intended for health care sales forces, which enable a smooth transition from a classical health care visit model towards a “hybrid” model, which brings a much higher return on investment. With this hybrid model, Health Care Professionals smartly mix face-to-face promotions of their products to the health care professional, and remote live e-detailing visits by combining telephone and internet. Founded in 2002, Kadrige has more than 50 employees and several clients in France and around the world among which are ranked in the top 20 pharmaceutical company ratings. For more information, please visit: www.kadrige.com.
This press release contains “forward-looking statements,” based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from expectations and projections. Risks and uncertainties include, among other things, general industry conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to product marketing, such as the unpredictability of market acceptance for new products; inconsistency of treatment results among patients; the potential for product failures; potential difficulties in manufacturing; governmental laws and regulations affecting domestic and foreign operations and the ongoing success of the collaboration. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required to do so by law.